Welcome to the e-CCO Library!

P327: Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Benítez J.M.*1, Barreiro-de Acosta M.2, Chaparro M.3, Vázquez J.M.4, Iglesias-Flores E.1, Tosca J.5, García-Planella E.6, García-Lόpez S.7, Taxonera C.8, Muñoz-Villafranca M.9, Pajares R.10, Barrio J.11, Arias L.12, Nantes O.13, Fernández-Salazar L.14, Hervías D.15, Martín-Arranz M.16, Mesonero F.17, Moraleja-Yudejo I.18, Pineda J.19, Argüelles-Arias F.20, Huguet J.21, Hernández-Martínez A.22, Pérez-Calle J.23, Leo E.24, Merino O.25, Van Domselaar M.26, Gutiérrez A.27, Lorente R.28, Castro M.29, Algaba A.30, Castro E.31, Robles-Alonso V.32, Ceballos D.33, Gόmez-García R.34, Domínguez J.35, Fernández E.36, Vega-Lόpez A.37, Trapero A.38, Talavera A.39, Royo V.40, Gisbert J.P.3, García-Sánchez V.1

Created: Wednesday, 20 February 2019, 10:36 AM
P327: Long-term effectiveness of ustekinumab in refractory Crohn's disease: an Italian multicenter real-life study
Year: 2021
Source: ECCO'21 Virtual
Authors: Scribano, M.L.(1);Aratari, A.(2);Neri, B.(3);Bezzio, C.(4);Balestrieri, P.(5);Falasco, G.(1);Camastra, C.(1);Pantanella, P.(1);Monterubbianesi, R.(1);Tullio, A.(5);Saibeni, S.(4);Papi, C.(2);Biancone, L.(3);Cosintino, R.(1);Faggiani, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P327: Segmental colectomy for ulcerative colitis: a new paradigm? A multi-centric study in 72 patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Frontali*1, Y. Panis1, L. Cohen2, V. Bridoux3, P. Myrelid4, G. Sica5, G. Poggioli6, E. Espin7, L. Beyer-Berjot8, D. Laharie9, A. Spinelli10, P. Zerbib11, G. Sampietro12, M. Frasson13, E. Louis14, X. Treton2

Created: Friday, 22 February 2019, 9:41 AM
P327: Symptom relevance attributed by inflammatory bowel disease patients has a differential impact on their quality of life
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Casellas*, C. Herrera de Guise, V. Robles, E. Navarro, M. Guirola, N. Borruel

Created: Thursday, 21 February 2019, 9:14 AM
P328 Faecal microbiota transplantation as treatment for recurrent Clostridiodes difficile infection in patients with inflammatory bowel disease: Experiences of the Netherlands donor faeces bank
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Van Lingen1, A.E. van der Meulen-de Jong1, K.E.W. Vendrik2, E.J. Kuijper2, E.M. Terveer2, J.J. Keller3

Created: Thursday, 30 January 2020, 10:12 AM
P328: Crohn’s colitis care (CCCare): development and testing of a bespoke cloud-based clinical management system for inflammatory bowel disease (IBD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Krishnaprasad1,2*, A. Walsh3, J. Begun4, S. Bell2, D. Carter5, R. Grafton6, A. Sechi7, K. Sewell8, A. McMahon8, S. Connor7, G. Radford-Smith1,8,9, J. Andrews6,10, ANZIBD Consortium, Crohn's Colitis Cure

Created: Thursday, 21 February 2019, 9:14 AM
P328: Factors related to short- and long-term treatment results and usefulness of infliximab for refractory ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Takada*, S. Yasukawa, R. Amano, M. Yasaka, N. Takatsu, Y. Yano, F. Hirai

Created: Friday, 22 February 2019, 9:49 AM
P328: Holistic well-being as Patient-reported outcomes (PROs) in translational IBD research: Prospective capture of CUCQ32 as study endpoints for mechanistic biomarker MUSIC/GIDAMPs study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hall, R.(1)*;Chuah, C.S.(1);Brownson, E.(2);Poulose, B.(1);Athena, O.(1);Mowat, C.(3);Macdonald, J.(2);Seenan, J.P.(2);Ho, G.T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P328: In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Perrigoue, J.(1);Muniz-Bongers, L.(1);Ong, L.(1);Chen, Y.(2);Chang, L.(2);Ngo, K.(2);Stojmirovic, A.(1);O’Brien, C.(1);Germinaro, M.(1);Rao, R.(1);Vetter, M.(1);Towne, J.(2);
Created: Friday, 11 February 2022, 3:52 PM
P328: Low vitamin K, vitamin D and calcium dietary intake in IBD patients represents a potentially reversible risk factor for osteoporosis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. S. Bertetti1, G. Burrelli Scotti1, M. T. Afferri1, V. Casali1, E. Cuofano1, C. Tortoriello1, A. De Carolis1, P. Vernia*1

Created: Friday, 22 February 2019, 9:41 AM
P328: Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Danese S.1, Gisbert J.P.2, Lobo A.J.3, Dignass A.4, Peyrin-Biroulet L.5, Kokot M.*6, Avedano L.7

Created: Wednesday, 20 February 2019, 10:36 AM
P328: Ustekinumab is an effective and safe therapy in anti-TNF refractory Crohn’s Disease: a two year real-life observational study from Spain
Year: 2021
Source: ECCO'21 Virtual
Authors: Rueda Sanchez, J.(1);Cabello Ramirez, M.(1);Camara Baena, S.(1);Keco Huerga, A.(1);Garcia de la Borbolla Serres, J.(1);Castro Fernandez, M.(1);Grande Santamaria, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P329 ECCO grant recipient: preliminary results of the HOT-TOPIC trial (Hyperbaric Oxygen Therapy for the Treatment Of Perianal fistulas In Crohn’s disease)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Lansdorp1, K. Gecse2, C. Buskens3, M. Löwenberg2, J. Stoker4, W. Bemelman3, G. D’Haens2, R. van Hulst1

Created: Thursday, 30 January 2020, 10:12 AM
P329: Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. B. Ruiz-Argüello1, A. Maguregui1, A. Martínez1, D. Nagore1

Created: Friday, 22 February 2019, 9:41 AM
P329: Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Marsilio, I.(1);MANIERO, D.(1);Lorenzon, G.(1);Rigo, A.(1);Cardin, R.(1);Facchin, S.(1);Barberio, B.(1);D'Incà, R.(1);Zingone, F.(1);Bahur, B.(2);Bray, K.B.(3);Savarino, E.V.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P329: Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

Created: Wednesday, 20 February 2019, 10:36 AM
P329: Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Hamanaka*, T. Nakagawa, H. Koseki, T. Sakurai, T. Taida, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura, T. Katsuno, M. Arai, O. Yokosuka

Created: Friday, 22 February 2019, 9:49 AM
P329: Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kutar, M.(1)*;Desai, D.(2);Abraham, P.(2);Gupta, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P329: Utility of faecal calprotectin to assess Crohn’s disease activity in patients with an ileostomy
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R. Rowan1*, S. Alzubi2, M. Healy3, G. Cullen4, H. Mulcahy4, J. Sheridan3,4, G.A. Doherty4

Created: Thursday, 21 February 2019, 9:14 AM
P329: Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
Year: 2022
Source: ECCO'22
Authors: Witjes, C.(1,2);Patel, A.(1,3);Zocche, D.(1);van 't Hullenaar- , C.(1);Cripps, S.(4);Travis, S.(5);George, B.(1);
Created: Friday, 11 February 2022, 3:52 PM